JPH07507997A - 遺伝子,腫瘍及びウイルス感染の治療,並びにプログラムされた細胞死(アポプトーシス)を予防するための方法及び組成物 - Google Patents
遺伝子,腫瘍及びウイルス感染の治療,並びにプログラムされた細胞死(アポプトーシス)を予防するための方法及び組成物Info
- Publication number
- JPH07507997A JPH07507997A JP5517439A JP51743993A JPH07507997A JP H07507997 A JPH07507997 A JP H07507997A JP 5517439 A JP5517439 A JP 5517439A JP 51743993 A JP51743993 A JP 51743993A JP H07507997 A JPH07507997 A JP H07507997A
- Authority
- JP
- Japan
- Prior art keywords
- gene
- cells
- hsv
- virus
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
Abstract
Description
Claims (33)
- 1.ニューロン細胞におけるプログラムされた細胞死を予防し又は治療する方法 であって: (a)γ134.5遺伝子を含む非病原性ベクターを調製し、 (b)非病原性ベクターを、プログラムされた細胞死を受けているか又は受けそ うなニューロン細胞に導入する ことを含む、上記の方法。
- 2.ベクターが、非病原性を与える方法により改変されたHSV−1又はHSV −2ウイルスを含む、請求の範囲第1項に記載の方法。
- 3.前記の改変が、HSV−1又はHSV−2ウイルスゲノムのICP4遺伝子 、α4遺伝子又はα0遺伝子の欠失を含む、請求の範囲第2項に記載の方法。
- 4.前記の改変が、HSV−1又はHSV−2ウイルスゲノムのICP4遺伝子 、α4遺伝子又はα0遺伝子の突然変異損傷を含む、請求の範囲第2項に記載の 方法。
- 5.前記のベクターが、改変されたレトロウイルス、ワクシニアウイルス、ピコ ルナウイルス、コロナウイルスエウニアウイルス、トガウイルス、又はラブドウ イルスを非病原性を与えるような方法で含む、請求の範囲第1項に記載の方法。
- 6.ベクターが多能性神経細胞系統を含む、請求の範囲第1項に記載の方法。
- 7.請求の範囲第6項に記載の多能性神経細胞系統の細胞を、前記のプログラム された細胞死を受けているか又は受けそうなニューロン細胞が位置する中枢神経 系の領域に移植することを含む方法によって、ベクターをプログラムされた細胞 死を受けているか又は受けそうなニューロン細胞に導入することを更に含む、請 求の範囲第1項に記載の方法。
- 8.細胞死を受けているか又は受けそうなニューロン細胞の末梢神経終末の部位 へのベクターの注射によって、ベクターを動物のニューロン細胞に導入すること を更に含む、請求項1に記載の方法。
- 9.ベクターをニューロン細胞とインキュベートすることによって、ベクターを 、細胞死を受けそうな又は受けている培養中のニューロン細胞へ導入することを 更に含む、請求の範囲第1項に記載の方法。
- 10.ウイルスベクターに非病原性を与えるゲノム改変を有するHSV−1又は HSV−2ウイルスを含むウイルスベクター。
- 11.前記のゲノム改変が、HSV−1又はHSV−2ゲノムのICP4遺伝子 、α4遺伝子又はα0遺伝子の欠失を含む、請求の範囲第10項に記載のウイル スベクター。
- 12.前記のゲノム改変が、HSV−1又はHSV−2ゲノムのICP4遺伝子 、α4遺伝子又はα0遺伝子の突然変異損傷を含む、請求の範囲第10項に記載 のウイルスベクター。
- 13.非病原性のレトロウイルス、ワクシニアウイルス、ピコルナウイルス、コ ロナウイルス、エウニアウイルス、トガウイルス、又はラブドウイルスを含むウ イルスベクター。
- 14.ニューロン細胞におけるプログラムされた細胞死を予防し又は治療する方 法であって: (a)ICP34.5又はその生物学的機能等価物を調製し、 (b)ICP34.5又はその生物学的機能等価物を製薬上許容し得るキャリア ーと組合せて製薬組成物を形成し、そして (c)その組成物を、プログラムされた細胞死を受けそうな又は受けているニュ ーロンに投与することを含む、上記の方法。
- 15.前記の製薬組成物が、ICP34.5又はその生物学的機能等価物を製薬 上許容し得るキャリアー中に含む、請求の範囲第14項に記載の製薬組成物。
- 16.ICP34.5又はその生物学的機能等価物を:(a)ICP34.5又 は生物学的機能等価物をコードし得る核酸断片を調製し、そして (b)その断片を発現させてICP34.5又は生物学的機能等価物蛋白質を製 造する ことを含む方法により調製する、請求の範囲第14項に記載の方法。
- 17.断片を宿主細胞にトランスファーして、その宿主細胞をその断片の発現に 適した条件下で培養する、請求の範囲第16項に記載の方法。
- 18.核酸断片を組換えベクターのトランスフェクション又はトランスフォーメ ーションによって宿主細胞にトランスファーする、請求の範囲第17項に記載の 方法。
- 19.蛋白質を単離し且つ精製することを更に含む、請求の範囲第17項に記載 の方法。
- 20.組成物を、直接の、髄腔又は静脈注射により、又は経口投与により、動物 に投与する、請求の範囲第14項に記載の方法。
- 21.組成物を蛋白質が細胞に入るように含む培地中で前記の細胞をインキュベ ートすることにより、組成物を培養中のニューロン細胞に投与する、請求の範囲 第14項に記載の方法。
- 22.細胞をプログラムされた細胞死から保護することの出来る候補物質の能力 を測定する方法であって:(a)プログラムされた細胞死に感受性のニューロン 細胞系統を調製し、 (b)前記の細胞系統を候補保護物質と合わせ、(c)インキュベーション溶液 を、細胞がプログラムされた細胞死を誘導し得る条件又は物質にさらされるよう に改変し、そして (d)候補物質が細胞をプログラムされた細胞死から保護したか否かを測定する ことを含む、上記の方法。
- 23.候補物質が、ICP34.5の推定の生物学的機能等価物である、請求の 範囲第22項に記載の方法。
- 24.ICP34.5又はその生物学的機能等価物の保護機能を強化する候補物 質の能力を測定する方法であって: (a)プログラムされた細胞死に感受性のニューロン細胞系統を調製し、 (b)前記の細胞系統の細胞を候補強化物質と合わせ、 (c)インキュベーション培地にICP34.5又はその生物学的機能等価物を 加え、 (d)インキュベーション溶液を、細胞がプログラムされた細胞死を誘導し得る 条件又は物質にさらされるように改変し、そして (e)候補物質がICP34.5又は生物学的機能等価物の保護効果を強化した か否かを測定することを含む、上記の方法。
- 25.γ134.5発現又はICP34.5若しくはその生物学的機能等価物の 活性のインヒビターとして作用する候補物質の能力を測定する方法であって:( a)プログラムされた細胞死に感受性のニューロン細胞系統を調製し、 (b)前記の細胞系統を候補阻害物質と合わせ、(c)インキュベーション培地 にICP34.5又はその生物学的機能等価物を加え、 (d)インキュベーション溶液を、細胞がプログラムされた細胞死を誘導し得る 条件又は物質にさらされるように改変し、そして (e)候補物質がICP34.5又は生物学的機能等価物の保護効果を阻止した か否かを測定することを含む、上記の方法。
- 26.遺伝子治療のために遺伝子を送達する方法であって: (a)遺伝子治療のための遺伝子を請求の範囲第10、11、12又は13項の 何れか1つに記載のベクターと結合させ、 (b)その遺伝子及びベクターを製薬上許容し得るキャリアーと組合せて製薬組 成物を形成し、そして(c)前記の製薬組成物を、遺伝子及びベクターが意図し た細胞標的に到達するように投与することを含む、上記の方法。
- 27.前記の製薬組成物を、動物への注射によって、前記の細胞標的の部位へ導 入する、請求の範囲第26項に記載の方法。
- 28.前記の細胞標的が中枢神経系にあり、製薬組成物を動物への注射によって 、前記の細胞標的の部位に位置するニューロンから始まる末梢神経終末の部位に 導入する、請求の範囲第26項に記載の方法。
- 29.前記の製薬組成物を髄腔内注射又は静脈注射によって導入する、請求の範 囲第26項に記載の方法。
- 30.遺伝子及び薬理学的に許容し得るキャリアーと組合せたベクターを含む、 請求の範囲第26項に記載の製薬組成物。
- 31.腫瘍形成性疾患又はウイルス感染を治療する方法であって: (a)請求の範囲第25項の候補物質を調製し、(b)その候補物質を製薬上許 容し得るキャリアーと組合せて製薬組成物を形成し、そして (c)その組成物を腫瘍細胞標的に投与することを含む、上記の方法。
- 32.製薬組成物を、注射によって、細胞標的の部位に直接投与するか、静脈注 射、髄腔内注射、又は経口により投与する、請求の範囲第31項に記載の方法。
- 33.製薬上許容し得るキャリアーと組合せた候補物質を含む、請求の範囲第3 1項に記載の製薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86123392A | 1992-03-31 | 1992-03-31 | |
US861,233 | 1992-03-31 | ||
PCT/US1993/001801 WO1993019591A1 (en) | 1992-03-31 | 1993-02-26 | Methods and compositions for gene, tumor, and viral infection therapy, and prevention of programmed cell death (apoptosis) |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006179944A Division JP2006335763A (ja) | 1992-03-31 | 2006-06-29 | 遺伝子、腫瘍及びウイルス感染の治療、並びにプログラムされた細胞死(アポトーシス)を予防するための方法及び組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07507997A true JPH07507997A (ja) | 1995-09-07 |
JP3974167B2 JP3974167B2 (ja) | 2007-09-12 |
Family
ID=25335240
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51743993A Expired - Fee Related JP3974167B2 (ja) | 1992-03-31 | 1993-02-26 | 遺伝子,腫瘍及びウイルス感染の治療,並びにプログラムされた細胞死(アポプトーシス)を予防するための方法及び組成物 |
JP2006179944A Pending JP2006335763A (ja) | 1992-03-31 | 2006-06-29 | 遺伝子、腫瘍及びウイルス感染の治療、並びにプログラムされた細胞死(アポトーシス)を予防するための方法及び組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006179944A Pending JP2006335763A (ja) | 1992-03-31 | 2006-06-29 | 遺伝子、腫瘍及びウイルス感染の治療、並びにプログラムされた細胞死(アポトーシス)を予防するための方法及び組成物 |
Country Status (10)
Country | Link |
---|---|
US (2) | US6172047B1 (ja) |
EP (1) | EP0675961B1 (ja) |
JP (2) | JP3974167B2 (ja) |
AT (1) | ATE228570T1 (ja) |
AU (1) | AU682463B2 (ja) |
CA (1) | CA2132976C (ja) |
DE (1) | DE69332525T2 (ja) |
DK (1) | DK0675961T3 (ja) |
ES (1) | ES2183811T3 (ja) |
WO (1) | WO1993019591A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016121157A (ja) * | 2009-12-18 | 2016-07-07 | バヴァリアン・ノルディック・アクティーゼルスカブ | 従来型樹状細胞によるifn‐ラムダの産生及びその使用 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770274B1 (en) | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
US6040169A (en) * | 1991-01-31 | 2000-03-21 | Medical Research Council | Herpes simplex virus-1 deletion variants and vaccines thereof |
US5763217A (en) * | 1993-11-10 | 1998-06-09 | University Of British Columbia | Method of using, process of preparing and composition comprising recombinant herpesvirus vectors |
US6699468B1 (en) * | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
GB9415320D0 (en) * | 1994-07-29 | 1994-09-21 | Medical Res Council | Cancer treatment |
US5834216A (en) * | 1995-09-06 | 1998-11-10 | Arch Development Corporation | Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis) |
AU6964596A (en) * | 1995-09-11 | 1997-04-01 | Arch Development Corporation | Materials and methods for treating neurodegenerative diseases and for screening for candidate apoptosis inhibitors and inducers |
AU1550797A (en) * | 1996-01-25 | 1997-08-20 | Medical Research Council | Treatment of non-neuronal cancer using hsv mutant |
GB9615794D0 (en) | 1996-07-26 | 1996-09-04 | Medical Res Council | Mutant herpes simplex virus strains and uses thereof |
JPH1087503A (ja) * | 1996-09-06 | 1998-04-07 | Nippon Chem Res Kk | 神経系腫瘍細胞のアポトーシス剤 |
PT1019524E (pt) * | 1997-01-31 | 2004-12-31 | Arch Dev Corp | Metodos para identificar indutores e inibidores da morte celular programada |
US5795713A (en) * | 1997-02-04 | 1998-08-18 | Arch Development Corporation | Methods for identifying inducers and inhibitors of programmed cell death |
US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
US20040151697A1 (en) * | 1998-01-08 | 2004-08-05 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
WO2000007618A2 (en) * | 1998-07-31 | 2000-02-17 | Centre De Recherche Du Centre Hospitalier De L'universite De Montreal | Anti-apoptotic compositions comprising the r1 subunit of herpes simplex virus ribonucleotide reductase or its n-terminal portion; and uses thereof |
US6774119B1 (en) * | 1999-04-26 | 2004-08-10 | Cedars-Sinai Medical Center | Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells |
US6897057B1 (en) * | 1999-08-31 | 2005-05-24 | The General Hospital Corporation | Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression |
ES2254359T3 (es) | 2000-01-21 | 2006-06-16 | Biovex Limited | Cepa viral para el tratamiento oncolitico de canceres. |
AU2003216502B2 (en) * | 2002-03-01 | 2008-04-10 | Sloan-Kettering Institute For Cancer Research | Prevention of recurrence and metastasis of cancer |
JP2004099584A (ja) * | 2002-05-02 | 2004-04-02 | Keio Gijuku | Hsvを用いた抗腫瘍剤 |
EP1552016A4 (en) * | 2002-09-23 | 2008-05-14 | Macrogenics Inc | VACCINE IDENTIFICATION METHODS AND VACCINATION COMPOSITIONS COMPRISING NUCLEIC ACID SEQUENCES AND / OR HERPES VIRUS FAMILY POLYPEPTIDES |
US7592169B2 (en) * | 2003-04-25 | 2009-09-22 | Medimmune, Llc | Methods and compositions for treatment and prevention of HSV-2 infections and conditions |
US7795419B2 (en) * | 2004-05-26 | 2010-09-14 | Rosetta Genomics Ltd. | Viral and viral associated miRNAs and uses thereof |
WO2006002394A2 (en) * | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
DE102005052622A1 (de) | 2005-11-02 | 2007-05-03 | Antonio Larcher | Vorrichtung zur Extraktion eines Angelhakens |
US20090273586A1 (en) * | 2008-04-30 | 2009-11-05 | Sony Ericsson Mobile Communications Ab | Device and method for composing and handling messages |
US10092626B2 (en) * | 2013-12-17 | 2018-10-09 | Yale University | Anti-infective properties of antifreeze protein |
SG10202108724YA (en) | 2016-01-08 | 2021-09-29 | Replimune Ltd | Modified oncolytic virus |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
US4859587A (en) * | 1984-06-04 | 1989-08-22 | Institut Merieux | Recombinant herpes simplex viruses, vaccines and methods |
CA2039921A1 (en) * | 1990-04-16 | 1991-10-17 | Xandra O. Breakefield | Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
US5328688A (en) * | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
US5360893A (en) | 1992-07-20 | 1994-11-01 | University Of Colorado Foundation, Inc. | DNA sequences encoding proteins used to elicit and detect programmed cell death |
US5593879A (en) | 1993-01-15 | 1997-01-14 | Massachusetts Institute Of Technology | Cell death genes of Drosophila melanogaster and vertebrate analogs |
US5585096A (en) * | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
-
1993
- 1993-02-26 EP EP93907093A patent/EP0675961B1/en not_active Revoked
- 1993-02-26 WO PCT/US1993/001801 patent/WO1993019591A1/en active IP Right Grant
- 1993-02-26 JP JP51743993A patent/JP3974167B2/ja not_active Expired - Fee Related
- 1993-02-26 AU AU37818/93A patent/AU682463B2/en not_active Ceased
- 1993-02-26 DK DK93907093T patent/DK0675961T3/da active
- 1993-02-26 DE DE69332525T patent/DE69332525T2/de not_active Expired - Lifetime
- 1993-02-26 AT AT93907093T patent/ATE228570T1/de not_active IP Right Cessation
- 1993-02-26 ES ES93907093T patent/ES2183811T3/es not_active Expired - Lifetime
- 1993-02-26 CA CA002132976A patent/CA2132976C/en not_active Expired - Fee Related
-
1995
- 1995-06-07 US US08/483,533 patent/US6172047B1/en not_active Expired - Fee Related
-
1999
- 1999-04-01 US US09/283,471 patent/US6340673B1/en not_active Expired - Fee Related
-
2006
- 2006-06-29 JP JP2006179944A patent/JP2006335763A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016121157A (ja) * | 2009-12-18 | 2016-07-07 | バヴァリアン・ノルディック・アクティーゼルスカブ | 従来型樹状細胞によるifn‐ラムダの産生及びその使用 |
Also Published As
Publication number | Publication date |
---|---|
DE69332525T2 (de) | 2003-04-17 |
DK0675961T3 (da) | 2003-03-24 |
US6172047B1 (en) | 2001-01-09 |
AU682463B2 (en) | 1997-10-09 |
AU3781893A (en) | 1993-11-08 |
US6340673B1 (en) | 2002-01-22 |
JP2006335763A (ja) | 2006-12-14 |
CA2132976A1 (en) | 1993-10-14 |
WO1993019591A1 (en) | 1993-10-14 |
CA2132976C (en) | 2003-12-30 |
EP0675961B1 (en) | 2002-11-27 |
ES2183811T3 (es) | 2003-04-01 |
DE69332525D1 (de) | 2003-01-09 |
EP0675961A1 (en) | 1995-10-11 |
EP0675961A4 (en) | 1996-02-28 |
ATE228570T1 (de) | 2002-12-15 |
JP3974167B2 (ja) | 2007-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07507997A (ja) | 遺伝子,腫瘍及びウイルス感染の治療,並びにプログラムされた細胞死(アポプトーシス)を予防するための方法及び組成物 | |
Dingwell et al. | Glycoproteins E and I facilitate neuron-to-neuron spread of herpes simplex virus | |
JP3334876B2 (ja) | 組換え単純ヘルペスウイルスワクチン及び方法 | |
Latchman | Gene delivery and gene therapy with herpes simplex virus-based vectors | |
JPH05505302A (ja) | 単純ヘルペス・ウィルスのタイプ1の変異体 | |
AU690601B2 (en) | Vector, viral protein, nucleotide sequence coding therefor and method for inhib iting immune recognition | |
Mao et al. | Strain-dependent structural variants of herpes simplex virus type 1 ICP34. 5 determine viral plaque size, efficiency of glycoprotein processing, and viral release and neuroinvasive disease potential | |
Chou et al. | Differential response of human cells to deletions and stop codons in the gamma (1) 34.5 gene of herpes simplex virus | |
US10806761B2 (en) | Oncolytic HSV1 vector and methods of use | |
Chowdhury et al. | Bovine herpesvirus 5 (BHV-5) Us9 is essential for BHV-5 neuropathogenesis | |
JP4044131B2 (ja) | ヘルペスウイルスワクチン | |
Orlando et al. | ICP22 is required for wild-type composition and infectivity of herpes simplex virus type 1 virions | |
JP4551042B2 (ja) | ヘルペスγ34.5遺伝子発現の細胞特異的および/または腫瘍特異的プロモーター再標的化 | |
Ben-Hur et al. | HSV-1 DNA sequence determining intraperitoneal pathogenicity in mice is required for transcription of viral immediate-early genes in macrophages | |
CN109563489A (zh) | 具有经修饰的糖蛋白d的疱疹病毒 | |
JPH09508788A (ja) | ヘルペスウイルス複製欠陥突然変異体 | |
WO1997010349A1 (en) | Materials and methods for treating neurodegenerative diseases and for screening for candidate apoptosis inhibitors and inducers | |
Koetters et al. | Mouse hepatitis virus strain JHM infects a human hepatocellular carcinoma cell line | |
KR20210139306A (ko) | 강력한 암 치료제로서의 융합체 종양용해성 단순 헤르페스 돌연변이체 | |
Miles | The role of ICP0 expression in reactivation of herpes simplex virus type 1 strains KOS-63 and KOS-79 | |
WO2005105833A2 (en) | Novel herpes simplex viruses and uses thereof | |
US20030017173A1 (en) | Arrestable therapeutic viral agent | |
JP2001513634A (ja) | 停止可能な治療用ウイルス製剤 | |
Weichselbaum et al. | Treatment of tumors with genetically engineered herpes virus | |
CN109837292A (zh) | 一种敲除pd1的靶向egfr的嵌合抗原受体t细胞及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040121 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040308 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060530 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060824 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070515 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070614 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100622 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110622 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |